Alzheimer’s Disease Progression: From Silent Biological Change to Cognitive Syndrome

Abstract

Alzheimer’s disease is increasingly understood as a long, biologically heterogeneous continuum rather than a condition that begins when dementia becomes visible. In many people, measurable changes related to amyloid-β and tau emerge years before clear cognitive symptoms. That interval is often described as preclinical Alzheimer’s disease, although the term does not mean that a future clinical syndrome is certain in every biomarker-positive person. Mild cognitive impairment (MCI) and dementia describe clinical states defined by the pattern and functional consequences of cognitive change; they are not interchangeable with a single molecular diagnosis. Biomarkers, neuropathology, genetics, longitudinal cohorts, and therapeutic trials have strengthened the case that amyloid and tau are central to Alzheimer biology. They have also made the simple “one pathway, one clock” account inadequate.

Current models place early amyloid-related change, later and more topographically extensive tau pathology, synaptic and neuronal injury, and eventual clinical impairment in a partially ordered but variable relationship. The amount and distribution of tau pathology often relate more closely to cognitive impairment than amyloid burden alone, while neurodegeneration and symptoms are shaped by vascular injury, inflammation, resilience, co-pathologies, education, sensory health, and other factors. Biological and clinical staging frameworks are valuable organizing tools, but they do not supply a precise individual timetable. This abstract explains how the preclinical, MCI, and dementia portions of the continuum relate to one another; what common biomarkers can and cannot show; and why careful language remains essential when translating research concepts for a general audience.

Educational notice: This abstract is for scientific education only. It is not medical advice, diagnosis, or treatment guidance.